Literature DB >> 27558360

Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.

Ahmet Emre Eskazan1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27558360     DOI: 10.1007/s00228-016-2122-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  4 in total

1.  Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?

Authors:  Ahmet Emre Eskazan; Isil Erdogan; Selin Berk; Fevzi Firat Yalniz; Tugrul Elverdi; Ayse Salihoglu; Teoman Soysal
Journal:  Leuk Lymphoma       Date:  2015-03-28

Review 2.  Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.

Authors:  Amina Haouala; Nicolas Widmer; Michel A Duchosal; Michael Montemurro; Thierry Buclin; Laurent A Decosterd
Journal:  Blood       Date:  2010-09-01       Impact factor: 22.113

3.  Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients.

Authors:  Fahri Sahin; Güray Saydam; Melda Cömert; Burak Uz; Akif Selim Yavuz; Esra Turan; Ipek Yönal; Hilmi Atay; Engin Keltikli; Mehmet Turgut; Mustafa Pehlivan; Meltem Olga Akay; Emel Gürkan; Semra Paydaş; Selda Kahraman; Fatih Demirkan; Onur Kırkızlar; Seval Akpınar; Gülsüm Emel Pamuk; Muzaffer Demir; Hasan Mücahit Ozbaş; Mehmet Sönmez; Mine Gültürk; Ayşe Salihoğlu; Ahmet Emre Eşkazan; Cem Ar; Handan Haydaroğlu Şahin; Seniz Ongören; Zafer Başlar; Yıldız Aydın; Mustafa Nuri Yenere; Nükhet Tüzüner; Burhan Ferhanoğlu; Ibrahim C Haznedaroglu; Osman Ilhan; Teoman Soysal
Journal:  Turk J Haematol       Date:  2013-12-05       Impact factor: 1.831

4.  A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib.

Authors:  Ferdows Atiq; Annoek E C Broers; Louise M Andrews; Jeanette K Doorduijn; Birgit C P Koch; Teun Van Gelder; Jorie Versmissen
Journal:  Eur J Clin Pharmacol       Date:  2016-03-11       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.